Cardioprotective mechanism of omega-3 polyunsaturated fatty acids

Journal of Cardiology

Volumn 67, Issue 1, 2016, Pages 22-27

  Endo, Jin ^a   Arita, Makoto ^b,c  

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Institute of Physical and Chemical Research   (Japan)

^c YOKOHAMA CITY UNIVERSITY   (Japan)

Author keywords

18 Hydroxyeicosapentaenoic acid; Anti inflammation; Cardiovascular disease; Omega 3 polyunsaturated fatty acids; Specialized proresolving mediators

Indexed keywords

ARACHIDONIC ACID; CALCIUM CHANNEL L TYPE; CELL NUCLEUS RECEPTOR; DOCOSAHEXAENOIC ACID; G PROTEIN COUPLED RECEPTOR; ICOSAPENTAENOIC ACID; LIPOXYGENASE; PROSTAGLANDIN SYNTHASE; ANTIARRHYTHMIC AGENT; ANTIINFLAMMATORY AGENT; CARDIOTONIC AGENT; OMEGA 3 FATTY ACID;

ANTIINFLAMMATORY ACTIVITY; CELL MEMBRANE; DIETARY INTAKE; ENZYME METABOLISM; HEART ARRHYTHMIA; HEART FAILURE; HEART INFARCTION; HEART PROTECTION; HUMAN; MEMBRANE FLUIDITY; NONHUMAN; PHOSPHOLIPID BILAYER; PRACTICE GUIDELINE; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; DRUG EFFECTS; VASCULAR REMODELING;

ANTI-ARRHYTHMIA AGENTS; ANTI-INFLAMMATORY AGENTS; CARDIOTONIC AGENTS; FATTY ACIDS, OMEGA-3; HUMANS; VASCULAR REMODELING;

EID: 84955187127     PISSN: 09145087     EISSN: 18764738     Source Type: Journal    
DOI: 10.1016/j.jjcc.2015.08.002     Document Type: Review

References (31)

1. Mozaffarian D., Wu J.H. Omega-3 fatty acids and cardiovascular disease: effects on risk factors, molecular pathways, and clinical events. J Am Coll Cardiol 2011, 58:2047-2067.
2. GISSI-Prevenzione Investigators (Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico) Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico. Lancet 1999, 354:447-455.
3. Tavazzi L., Maggioni A.P., Marchioli R., Barlera S., Franzosi M.G., Latini R., Lucci D., Nicolosi G.L., Porcu M., Tognoni G. Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet 2008, 372:1223-1230.
4. Yokoyama M., Origasa H., Matsuzaki M., Matsuzawa Y., Saito Y., Ishikawa Y., Oikawa S., Sasaki T., Hishida H., Itakura H., Kita T., Kitabatake A., Nakaya N., Sakata T., Shimada K., et al. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis. Lancet 2007, 369:1090-1098.
5. Kris-Etherton P.M., Harris W.S., Appel L.J. American Heart Association. Nutrition Committee. Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease. Circulation 2002, 106:2747-2757.
6. Mozaffarian D., Wu J.H. Omega-3 fatty acids and cardiovascular disease: effects on risk factors, molecular pathways, and clinical events. J Am Coll Cardiol 2011, 58:2047-2067.
7. Fan Y.Y., Ly L.H., Barhoumi R., McMurray D.N., Chapkin R.S. Dietary docosahexaenoic acid suppresses T cell protein kinase C theta lipid raft recruitment and IL-2 production. J Immunol 2004, 173:6151-6160.
8. Wong S.W., Kwon M.J., Choi A.M., Kim H.P., Nakahira K., Hwang D.H. Fatty acids modulate Toll-like receptor 4 activation through regulation of receptor dimerization and recruitment into lipid rafts in a reactive oxygen species-dependent manner. J Biol Chem 2009, 284:27384-27392.
9. Xiao Y.F., Kang J.X., Morgan J.P., Leaf A. Blocking effects of polyunsaturated fatty acids on Na+ channels of neonatal rat ventricular myocytes. Proc Natl Acad Sci U S A 1995, 92:11000-11004.
10. Hallaq H., Smith T.W., Leaf A. Modulation of dihydropyridine-sensitive calcium channels in heart cells by fish oil fatty acids. Proc Natl Acad Sci U S A 1992, 89:1760-1764.
11. Xiao Y.F., Ke Q., Wang S.Y., Auktor K., Yang Y., Wang G.K., Morgan J.P., Leaf A. Single point mutations affect fatty acid block of human myocardial sodium channel alpha subunit Na+ channels. Proc Natl Acad Sci U S A 2001, 98:3606-3611.
12. Macchia A., Grancelli H., Varini S., Nul D., Laffaye N., Mariani J., Ferrante D., Badra R., Figal J., Ramos S., Tognoni G., Doval H.C. GESICA Investigators. Omega-3 fatty acids for the prevention of recurrent symptomatic atrial fibrillation: results of the FORWARD (Randomized Trial to Assess Efficacy of PUFA for the Maintenance of Sinus Rhythm in Persistent Atrial Fibrillation) trial. J Am Coll Cardiol 2013, 61:463-468.
13. Nodari S., Triggiani M., Campia U., Manerba A., Milesi G., Cesana B.M., Gheorghiade M., Dei Cas L. Effects of n-3 polyunsaturated fatty acids on left ventricular function and functional capacity in patients with dilated cardiomyopathy. J Am Coll Cardiol 2011, 57:870-879.
14. Zhao Y., Joshi-Barve S., Barve S., Chen L.H. Eicosapentaenoic acid prevents LPS-induced TNF-alpha expression by preventing NF-kappaB activation. J Am Coll Nutr 2004, 23:71-78.
15. Gani O.A., Sylte I. Molecular recognition of docosahexaenoic acid by peroxisome proliferator-activated receptors and retinoid-X receptor alpha. J Mol Graph Model 2008, 27:217-224.
16. Oh D.Y., Talukdar S., Bae E.J., Imamura T., Morinaga H., Fan W., Li P., Lu W.J., Watkins S.M., Olefsky J.M. GPR120 is an omega-3 fatty acid receptor mediating potent anti-inflammatory and insulin-sensitizing effects. Cell 2010, 142:687-698.
17. Oh D.Y., Walenta E., Akiyama T.E., Lagakos W.S., Lackey D., Pessentheiner A.R., Sasik R., Hah N., Chi T.J., Cox J.M., Powels M.A., Di Salvo J., Sinz C., Watkins S.M., Armando A.M., et al. A Gpr120-selective agonist improves insulin resistance and chronic inflammation in obese mice. Nat Med 2014, 20:942-947.
18. Yan Y., Jiang W., Spinetti T., Tardivel A., Castillo R., Bourquin C., Guarda G., Tian Z., Tschopp J., Zhou R. Omega-3 fatty acids prevent inflammation and metabolic disorder through inhibition of NLRP3 inflammasome activation. Immunity 2013, 38:1154-1163.
19. Chen J., Shearer G.C., Chen Q., Healy C.L., Beyer A.J., Nareddy V.B., Gerdes A.M., Harris W.S., O'Connell T.D., Wang D. Omega-3 fatty acids prevent pressure overload-induced cardiac fibrosis through activation of cyclic GMP/protein kinase G signaling in cardiac fibroblasts. Circulation 2011, 123:584-593.
20. Dyerberg J., Bang H.O., Stoffersen E., Moncada S., Vane J.R. Eicosapentaenoic acid and prevention of thrombosis and atherosclerosis?. Lancet 1978, 2:117-119.
21. Serhan C.N. Pro-resolving lipid mediators are leads for resolution physiology. Nature 2014, 510:92-101.
22. White P.J., St-Pierre P., Charbonneau A., Mitchell P.L., St-Amand E., Marcotte B., Marette A. Protectin DX alleviates insulin resistance by activating a myokine-liver glucoregulatory axis. Nat Med 2014, 20:664-669.
23. Merched A.J., Ko K., Gotlinger K.H., Serhan C.N., Chan L. Atherosclerosis: evidence for impairment of resolution of vascular inflammation governed by specific lipid mediators. FASEB J 2008, 22:3595-3606.
24. Hasturk H., Abdallah R., Kantarci A., Nguyen D., Giordano N., Hamilton J., Van Dyke T.E. Resolvin E1 attenuates atherosclerotic plaque formation in diet and inflammation-induced atherogenesis. Arterioscler Thromb Vasc Biol 2015, 35:1123-1133.
25. Keyes K.T., Ye Y., Lin Y., Zhang C., Perez-Polo J.R., Gjorstrup P., Birnbaum Y. Resolvin E1 protects the rat heart against reperfusion injury. Am J Physiol Heart Circ Physiol 2010, 299:153-164.
26. Kain V., Ingle K.A., Colas R.A., Dalli J., Prabhu S.D., Serhan C.N., Joshi M., Halade G.V. Resolvin D1 activates the inflammation resolving response at splenic and ventricular site following myocardial infarction leading to improved ventricular function. J Mol Cell Cardiol 2015, 84:24-35.
27. Spector A.A., Kim H.Y. Cytochrome P450 epoxygenase pathway of polyunsaturated fatty acid metabolism. Biochim Biophys Acta 2015, 1851:356-365.
28. Liu Y1, Wang R., Li J., Rao J., Li W., Falck J.R., Manthati V.L., Medhora M., Jacobs E.R., Zhu D. Stable EET urea agonist and soluble epoxide hydrolase inhibitor regulate rat pulmonary arteries through TRPCs. Hypertens Res 2011, 34:630-639.
29. Endo J., Sano M., Isobe Y., Fukuda K., Kang J.X., Arai H., Arita M. 18-HEPE, an n-3 fatty acid metabolite released by macrophages, prevents pressure overload-induced maladaptive cardiac remodeling. J Exp Med 2014, 211:1673-1687.
30. Kang J.X., Wang J., Wu L., Kang Z.B. Transgenic mice: fat-1 mice convert n-6 to n-3 fatty acids. Nature 2004, 427:504.
31. Kang J.X. A transgenic mouse model for gene-nutrient interactions. J Nutrigenet Nutrigenomics 2008, 1:172-177.